Form 4: Allogene Therapeutics CEO David Chang Acquires 344,828 Shares in Direct Offering

Allogene Therapeutics CEO David Chang acquired 344,828 shares of common stock through a registered direct offering at a price of $2.9 per share.

Summary

• On May 16, 2024, David Chang, the President and CEO of Allogene Therapeutics, acquired 344,828 shares of Allogene Therapeutics common stock.
• The shares were purchased directly from Allogene Therapeutics in a registered direct offering.
• The purchase price was $2.9 per share.
• Following the transaction, Mr. Chang directly owns 4,810,106 shares of common stock.
• Mr. Chang also indirectly owns shares through several trusts: 1,201,108 shares via the Chang 2006 Family Trust, 856,044 shares via the JEC 2019 Trust, and 856,044 shares via the RTC 2019 Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares indicates confidence, but the direct offering itself is a fairly standard financial transaction.

Positives

• The CEO's direct purchase of shares may signal confidence in the company's future prospects.

Industry Context

Direct offerings are a common way for companies in the biotechnology industry to raise capital. Insider purchases can be viewed positively by the market.

Stakeholder Impact

• The CEO's purchase could positively influence shareholder sentiment.

Key Dates